Tribe Clinical Research, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$312,394	45
2024	Research	$263,362	10
2023	Research	$768,190	35
2022	Research	$143,771	23
2021	Research	$414,830	18
2020	Research	$4,204	4

Breakdown

Who paid Research payments · program years 2020–2025

Merck Sharp & Dohme Corporation $1,320,328 52 payments
Abbott Laboratories $272,971 62 payments
Novartis Pharmaceuticals Corporation $228,919 4 payments
AstraZeneca Pharmaceuticals LP $32,949 6 payments
AstraZeneca UK Limited $26,084 8 payments
Sun Pharmaceutical Industries Inc. $18,000 1 payment
Rapid Pathogen Screening, Inc. $7,500 2 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $433,514 9 payments
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in 16- to 26-Year Old Women $382,852 11 payments
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease $274,133 10 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $197,714 3 payments
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) $171,882 36 payments
A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants $101,227 6 payments
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening $75,410 20 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 Laboratory-confirmed SARS-CoV-2 Infection With Symptoms in Adults Residing With a Person With COVID-19 $58,607 5 payments
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $31,205 1 payment
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). $31,133 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.